Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.34 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.34 |
| ▸ | F2R | P25116 | 5/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.32 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.32 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.32 |
| ▸ | GCGR | P47871 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL786890 | 0.92 | EPHX2 (0.38) | HRH3ITGB3ITGA2BEPHX2PRMT5 | |
| SCHEMBL770357 | 0.86 | EPHX2 (0.39) | HRH3EPHX2LMNASMN1; SMN2 | |
| SCHEMBL770193 | 0.82 | EPHX2 (0.41) | HRH3EPHX2LMNASMN1; SMN2 | |
| SCHEMBL771680 | 0.82 | DPP4 (0.32) | ITGB3ITGA2BLMNA | |
| SCHEMBL770219 | 0.81 | NOTUM (0.38) | LMNASMN1; SMN2 | |
| SCHEMBL770545 | 0.79 | RBP4 (0.35) | SMN1; SMN2 | |
| SCHEMBL770693 | 0.78 | ITGB3 (0.35) | HRH3ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL15224149 | 0.78 | FFAR4 (0.37) | HRH3ITGB3ITGA2B | |
| SCHEMBL15121653 | 0.77 | FAAH (0.35) | ITGB3ITGA2B | |
| SCHEMBL771484 | 0.77 | LMNA (0.30) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822452-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2014-09-02 | — | — | US | disclosed |
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-11-14 | — | — | US | disclosed |
| US-8524894-B2 | Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 | LABORATORIOS SALVAT, S.A. (ES) | 2013-09-03 | — | — | US | disclosed |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | LABORATORIOS SALVAT, S.A. (ES) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303522-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HRH3 1687/4885ITGB3 4856/4885ITGA2B 4854/4885 |
| US-20120071466-A1 | INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD17B1, HSD11B2 | HRH3 1698/4885ITGB3 4856/4885ITGA2B 4849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.